Vasile Gaborean

Background/Objectives: Anatomical lung resection removes part of the pulmonary vascular bed and may acutely alter right ventricular loading conditions. The magnitude and the clinical significance of these early changes remain incompletely characterized, and it is unclear whether early echocardiographic changes relate to postoperative complications. This study aimed primarily to characterize the perioperative echocardiographic response to lung resection, while associations with any postoperative complication and with a cardiopulmonary composite outcome were evaluated as a secondary, exploratory analysis. Methods: This prospective, single-center observational study included 40 adult patients undergoing lung resection for suspected or confirmed lung cancer. Transthoracic echocardiography was performed preoperatively and on the first postoperative day, and N-terminal pro–B-type natriuretic peptide (NT-proBNP) was measured preoperatively and at 24 h. Assessed parameters included left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (PASP), peak tricuspid regurgitation velocity (TRV), the TAPSE/PASP coupling ratio and NT-proBNP. The primary outcome was the paired perioperative change in those measurements. Paired comparisons used the Wilcoxon signed-rank test with matched-pairs rank-biserial correlations and bootstrap confidence intervals; exploratory comparisons used Mann–Whitney U tests and areas under the receiver operating characteristic curve (AUC) with bootstrap confidence intervals. Multivariable modeling was not performed. Results: All six parameters changed significantly between the preoperative and postoperative assessments. PASP increased by a median of 4.0 mmHg (p < 0.001) and TRV max by 0.10 m/s (p < 0.001), while TAPSE decreased by 0.10 cm (p = 0.015) and LVEF by 2.0 percentage points (p = 0.001). The right ventricular–pulmonary arterial (RV–PA) coupling ratio declined from 0.717 to 0.526 mm/mmHg (p < 0.001) and NT-proBNP rose from 82.5 to 229.0 pg/mL (p < 0.001). Sixteen patients (40.0%) developed any complication and seven (17.5%) developed a cardiopulmonary complication. No echocardiographic parameter showed statistically supported discrimination for either outcome; all corresponding confidence intervals for the AUC included 0.50. NT-proBNP measured at 24 h and its perioperative change showed nominal associations with complication status, whereas the preoperative concentration did not. All recorded complications were documented before the 24-h blood draw. Conclusions: Anatomical lung resection was followed by statistically detectable changes in measured echocardiographic indices by the first postoperative day. The cohort-level increase in pulmonary pressures and the decline in RV–PA coupling were the most clearly supported findings, whereas the small changes in TAPSE and LVEF are of uncertain biological magnitude. No echocardiographic parameter showed statistically supported discrimination between patients who did and did not develop complications, as estimates were imprecise, with wide confidence intervals. The association with 24-h NT-proBNP was post-event and therefore cannot be interpreted as evidence of predictive value.

Background: NT-proBNP is a mechanistically grounded biomarker of ventricular wall stress with established prognostic value in cardiac surgery, but its perioperative role in lung cancer resection remains incompletely characterised. Pulmonary resection imposes unique haemodynamic stressors—including one-lung ventilation-induced right ventricular afterload increase, permanent pulmonary vascular bed reduction, and ischaemia–reperfusion injury—that create a distinct biological context for natriuretic peptide elevation not represented in general surgical cohorts. Methods: A narrative review of the literature was conducted through systematic searches of PubMed, EMBASE/MEDLINE, and the Cochrane Library (January 2000–June 2026), supplemented by manual reference screening. Approximately 135 articles were included in the final synthesis. Results: Perioperative NT-proBNP elevation predicts postoperative atrial fibrillation, major adverse cardiovascular events, and long-term survival after lung resection, with effect sizes substantially exceeding those reported in general surgical populations. The PRESAGE trial established that NT-proBNP-guided prophylaxis reduces postoperative atrial fibrillation from 40% to 6% in high-risk patients. No thoracic surgery-specific NT-proBNP threshold has been prospectively validated in a multicentre setting, and approximately half the evidence base derives from BNP rather than NT-proBNP assays, precluding direct threshold synthesis. Surgical approach—particularly robot-assisted thoracoscopy—modulates postoperative biomarker elevation through OLV duration rather than inflammatory burden alone. The combination of NT-proBNP with high-sensitivity troponin identifies a dual-elevation subgroup with a MACE rate of 18.4%. Conclusions: NT-proBNP measurement is clinically actionable in thoracic surgery but requires assay-standardised, multicentre validation of population-specific thresholds stratified by resection extent and surgical approach. A dual biomarker strategy combining NT-proBNP with high-sensitivity troponin represents the most evidence-based perioperative risk stratification framework currently available.

Background/Objectives: major open abdominal surgery remains associated with clinically important postoperative pain, delayed gastrointestinal recovery, opioid exposure, and prolonged length of stay. Intravenous lidocaine infusion (IVLI) has biologically plausible analgesic, anti-hyperalgesic, anti-inflammatory, and opioid-sparing effects, but prior evidence syntheses have often combined open and minimally invasive procedures. This systematic review evaluated evidence for perioperative IVLI in adult patients undergoing major open abdominal surgery. Methods: the review was structured according to PRISMA 2020. The final search was run on 15 January 2026 and covered PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP from database inception to that date, without language restrictions at the search stage. Eligible studies enrolled adults undergoing elective open abdominal surgery and compared systemic IVLI with placebo, usual care, or active epidural analgesic comparators. Primary outcomes were postoperative opioid consumption and pain intensity. Secondary outcomes included gastrointestinal recovery, postoperative ileus, length of hospital stay, postoperative nausea and vomiting, inflammatory/stress biomarkers, and adverse events. Results: ten randomized trials involving 658 participants were included. Placebo/usual-care trials and active-comparator trials were synthesized separately because they address different clinical questions. IVLI generally reduced opioid consumption compared with placebo, with extractable effects including a 55.9 mg reduction in 72 h morphine use in one abdominal surgery trial and a 13.9 mg reduction in 24 h morphine use after radical prostatectomy. Gastrointestinal recovery favored IVLI in most placebo-controlled studies; for example, first flatus occurred 12.5 h earlier and first bowel movement 28.4 h earlier in one trial. Active-comparator trials suggested comparable early dynamic pain outcomes versus thoracic epidural analgesia in selected settings, although opioid consumption findings were less consistent. No serious lidocaine-related toxicity was reported, but the included trials were underpowered to detect rare local anesthetic systemic toxicity events and did not consistently capture subclinical neurologic symptoms such as perioral numbness or visual disturbance. Conclusions: in adult open abdominal surgery, perioperative IVLI may provide opioid-sparing and recovery benefits, particularly when infusion continues beyond the intraoperative period. However, the certainty of evidence remains limited.

Background and Objectives: Post-hepatectomy liver failure (PHLF) remains the leading cause of mortality following hepatic resection, with reported incidence rates ranging from 1.2% to 32%. Traditional scoring systems such as the Child–Pugh score, Model for End-Stage Liver Disease (MELD), and Albumin–Bilirubin (ALBI) grade have demonstrated limited predictive accuracy for PHLF. Machine learning (ML) algorithms have emerged as promising tools capable of integrating complex, multidimensional clinical data to improve predictive performance. This systematic review aims to evaluate the current evidence on ML-based prediction models for PHLF, assessing their predictive accuracy, methodological quality, clinical applicability, and the key variables utilized across models. Methods: A systematic literature search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library from inception to January 2026. Studies that developed or validated ML models for predicting PHLF after hepatic resection were included. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was used to evaluate the risk of bias. Data on model performance, algorithms employed, sample sizes, predictor variables, and validation strategies were extracted. The review was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO. Results: Twelve PubMed-verified studies involving 6913 patients were retained in the final analysis. Publication years ranged from 2020 to 2025, with five studies published in 2025. Gradient boosting approaches (LightGBM/XGBoost or phase-specific boosting models) were the most frequent best-performing architectures, while ANN/deep learning, radiomics-integrated, and ensemble approaches also showed clinically relevant discrimination. Best reported non-training AUCs ranged from 0.7927 to 0.981 (median, 0.873). The strongest generalization signals came from studies with temporal, external, or prospective validation structures. Common predictor domains included bilirubin-based liver function measures, coagulation variables, platelet count, volumetry or extent of resection, imaging-derived radiomics features, and perioperative dynamic data. Conclusions: Machine learning models remain promising for PHLF prediction, but the evidence base is smaller and more heterogeneous than the original draft suggested. Performance is highest in studies that combine clinical liver-reserve markers with imaging or perioperative temporal data; however, widespread clinical adoption is still limited by retrospective design predominance, inconsistent outcome definitions, and incomplete external validation.

Background/Objectives: High-grade serous ovarian carcinoma (HGSOC) is associated with high relapse rates despite aggressive multimodal treatment. BRCA mutations, present in a substantial subset of patients, confer homologous recombination deficiency and increased sensitivity to platinum-based chemotherapy. This study evaluated the association between BRCA mutation status and clinical outcomes, focusing on dissemination patterns, treatment allocation, perioperative parameters, and progression-free survival (PFS). Methods: This prospective single-center cohort included 133 consecutive patients with newly diagnosed HGSOC treated between January 2020 and December 2025. Primary treatment strategy (primary debulking surgery [PDS] or neoadjuvant chemotherapy [NACT]) was determined by multidisciplinary assessment. BRCA testing was performed using tumor tissue or germline analysis. Patients were followed for 24 months. PFS was analyzed using Kaplan–Meier estimates and Cox regression models. Results: Pathogenic BRCA mutations were identified in 39.1% of patients. BRCA-mutated tumors demonstrated significantly lower rates of peritoneal carcinomatosis (50% vs. 77.77%, p = 0.001) and were more frequently managed with PDS (59.6% vs. 41.8%, p = 0.048). Perioperative outcomes were comparable between groups. Disease progression occurred less frequently in BRCA-mutated patients (32.69% vs. 51.85%, p = 0.017). In univariate analysis, BRCA mutation was associated with a 48% reduction in progression risk (HR 0.52, 95% CI 0.27–0.99, p = 0.048). After adjustment for age, FIGO stage, and residual disease, BRCA mutation was not independently associated with progression (HR 0.57, p = 0.124), although a protective trend was observed, while residual disease remained a significant predictor. Conclusions: In this prospective cohort, BRCA mutation status was associated with distinct dissemination patterns and a significant reduction in progression risk in HGSOC. Although residual disease remained the strongest independent prognostic factor after multivariable adjustment, a trend toward improved PFS observed among BRCA-mutated patients supports the role of homologous recombination deficiency as a meaningful modifier of disease trajectory. These findings reinforce the clinical relevance of molecular stratification in the contemporary management of HGSOC.

Background and Objectives: Intraoperative assessment of tissue perfusion remains a decisive but imperfect step in abdominal surgery. Surgeons still rely heavily on visual judgement when choosing bowel transection lines, constructing anastomoses, judging intestinal viability, or assessing graft reperfusion, even though these decisions are directly linked to anastomotic leak, conduit ischemia, postoperative liver dysfunction, and graft failure. Hyperspectral imaging (HSI) is an emerging contrast-free optical technology that generates quantitative maps of tissue oxygenation, hemoglobin distribution, water content, and near-infrared perfusion. The present review was designed to evaluate whether clinical intraoperative HSI has matured sufficiently to support a focused systematic review topic in abdominal surgery and to synthesize the currently available human evidence. Methods: A literature search was conducted up to 20 February 2026 using combinations of the terms “hyperspectral imaging”, “HSI”, “abdominal surgery”, “colorectal”, “hepatectomy”, “transplantation”, “pancreatoduodenectomy”, “esophagectomy”, “mesenteric ischemia”, and “intraoperative”. Eligible records were original human clinical studies evaluating intraoperative HSI in abdominal or transplant-related operations with perfusion, oxygenation, or tissue viability as a central endpoint. Review articles, animal studies, non-surgical diagnostic studies, and single-patient case reports were excluded. Data were synthesized narratively because of major heterogeneity in indications, designs, devices, timing of measurements, and reported outcomes. Results: Thirteen studies published between 2019 and 2024 met the eligibility criteria, representing 391 patients. The literature covered colorectal resection, acute mesenteric ischemia, esophageal reconstruction with gastric or colonic conduits, pancreatoduodenectomy, pancreas transplantation, major hepatectomy, liver transplantation, and minimally invasive system validation. Across colorectal studies, HSI frequently demonstrated discordance between visually selected and objectively perfused transection lines, with clinically relevant strategy changes in a substantial proportion of patients. In ischemic and transplant settings, HSI discriminated poorly perfused tissue, identified low near-infrared perfusion values associated with early allograft dysfunction, and quantified reperfusion patterns after clamping or implantation. The evidence base was dominated by prospective single-center feasibility studies with small to moderate sample sizes, and no randomized trials were identified. Conclusions: Clinical intraoperative HSI in abdominal surgery is a genuinely niche yet rapidly expanding topic with a sufficient number of human studies to support a relevant systematic review. Current evidence consistently supports feasibility, quantitative perfusion discrimination, and plausible intraoperative utility, especially in colorectal and transplant-related surgery. However, the field remains methodologically heterogeneous, and the next research priority is multicenter standardization with clinically anchored thresholds and outcome-driven comparative studies.

Background/Objectives: High-grade serous ovarian cancer (HGSOC) represents the most aggressive subtype of epithelial ovarian cancer and is frequently diagnosed at advanced stages. Increasing evidence suggests that systemic inflammation plays an important role in tumor progression and clinical outcomes. This study aimed to evaluate the association between preoperative systemic inflammatory indices and tumor burden, perioperative outcomes, and recurrence risk in patients with HGSOC undergoing primary debulking surgery. Methods: We conducted a retrospective study including 125 patients with histopathologically confirmed HGSOC who underwent primary debulking surgery between January 2020 and December 2025. Preoperative hematological parameters obtained within 24 h before surgery were used to calculate inflammatory indices including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI). Associations between inflammatory markers, clinicopathological characteristics, perioperative outcomes, and recurrence were analyzed using non-parametric tests and logistic regression models. Results: The mean patient age was 53.66 ± 9.14 years, and most patients presented with advanced disease (FIGO III–IV: 70.4%). Patients with T3 tumors showed significantly higher monocyte (0.66 vs. 0.50 × 10⁹/L, p = 0.003), neutrophil (5.43 vs. 4.99 × 10⁹/L, p = 0.042), and platelet counts (325 vs. 280 × 10⁹/L, p = 0.006) and lower lymphocyte counts (1.79 vs. 1.96 × 10⁹/L, p = 0.009). Composite inflammatory indices were also increased in advanced disease, including PLR (177 vs. 153, p = 0.009), AISI (492 vs. 341, p = 0.002), and SIRI (1.65 vs. 1.18, p = 0.018). Patients requiring postoperative blood transfusion had higher neutrophil counts (7.65 vs. 4.97 × 10⁹/L, p < 0.001) and elevated SIRI (2.56 vs. 1.55, p < 0.001). Patients with recurrence had significantly higher platelet counts (339 vs. 293 × 10⁹/L, p = 0.001) and SII values (2849 vs. 2586, p = 0.012). In multivariate analysis, SII remained independently associated with recurrence (OR 1.022 per 100-unit increase; 95% CI 1.002–1.043; p = 0.033) together with advanced FIGO stages (OR 2.863; 95% CI 1.011–8.104; p = 0.048). Conclusions: Preoperative systemic inflammatory markers are significantly associated with tumor burden, surgical outcomes, and recurrence risk in HGSOC. An elevated SII appears to be an independent predictor of recurrence and may represent a practical biomarker for improving preoperative risk stratification and postoperative surveillance.

Background: Acute cholecystitis, a leading cause of urgent surgical intervention, poses challenges in predicting severity and operative complexity. This study characterized the immuno-inflammatory profile distinguishing acute from chronic cholecystitis and assessed whether blood-derived ratios—neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR)—correlate with histologic severity and surgical difficulty. Methods: The study retrospectively analyzed 759 patients undergoing cholecystectomy from 2016 to 2024. Inflammatory indices from preoperative bloodwork were compared across histopathologic subtypes (catarrhal, phlegmonous, gangrenous), clinical features, and surgical outcomes, including conversion to open procedure. Logistic regression and ROC analyses identified predictors of acute inflammation and conversion. Results: Acute cholecystitis patients showed elevated NLR (7.0 vs. 3.1), MLR (0.44 vs. 0.26), and PLR (194 vs. 142; all p < 0.001). NLR was the only independent predictor of acute disease (OR = 1.29, 95% CI 1.203–1.390, p < 0.001), with superior discrimination (AUC = 0.806, cut-off = 3.56; sensitivity 73.1%, specificity 80.4%). NLR and PLR rose progressively from catarrhal to phlegmonous and gangrenous subtypes (p < 0.05), mirroring conversion rates (0% catarrhal, 3.2% phlegmonous, 10.5% gangrenous; p = 0.001). Conclusions: Routine hematologic ratios capture systemic immune activation in acute cholecystitis, reflecting histologic severity and operative risk. NLR, integrating innate and adaptive immune dynamics, offers a practical biomarker for preoperative risk stratification in acute care surgery.

Background and Objectives: High-grade serous ovarian carcinoma (HGSOC) remains the most lethal gynecologic malignancy, with outcomes heavily dependent on early diagnosis and timely multimodal treatment. The COVID-19 pandemic profoundly disrupted oncologic care, leading to diagnostic delays, modified treatment algorithms, and deferred surgeries. This study aimed to assess how these disruptions influenced disease presentation, surgical complexity, and postoperative outcomes during the pandemic and post-pandemic periods in a Romanian tertiary oncology center. Materials and Methods: A retrospective, single-center cohort analysis was conducted on 112 patients with histologically confirmed HGSOC who underwent surgical treatment between 26 February 2020 and 25 February 2024. The cohort was divided into two equal groups: a pandemic cohort (2020–2022) and a post-pandemic cohort (2022–2024). Clinical, pathological, and therapeutic parameters were compared, including FIGO and T staging, surgical duration, ICU admissions, and treatment intervals. Results: The post-pandemic period was marked by a significant rise in advanced-stage presentations (FIGO IV: 17.8% vs. 33.9%, p = 0.003), peritoneal carcinomatosis (58.9% vs. 82.1%, p = 0.004), and multiorgan invasion (7.1% vs. 16.0%, p = 0.039). Mean operative time increased significantly post-pandemic (94.0 ± 36.3 vs. 123.5 ± 52.5 min, p = 0.003), as did ICU admissions (35.7% vs. 60.7%, p = 0.002). While the number of neoadjuvant and adjuvant chemotherapy cycles remained consistent between cohorts, a greater surgical complexity and longer postoperative recovery characterized the post-pandemic cases, suggesting cumulative disease progression and increased treatment demands. Conclusions: The findings indicate an association between the post-pandemic period and more advanced disease profiles at presentation, as well as increased surgical complexity, highlighting potential long-term effects of healthcare disruption. These results highlight the necessity for resilient cancer care systems emphasizing early detection, multidisciplinary coordination, and adaptive treatment models to mitigate future systemic disruptions and preserve survival outcomes in women with HGSOC.

Background/Objectives: Acute calculous cholecystitis remains one of the most frequent surgical emergencies, ranging from mild inflammation to gangrenous forms associated with necrosis and sepsis. Early differentiation between these stages is essential for timely surgical management. This study aimed to evaluate the diagnostic and prognostic value of hematological inflammatory indices—the Aggregate Index of Systemic Inflammation (AISI), the Systemic Immune-Inflammation Index (SII), and the Systemic Inflammation Response Index (SIRI)—in predicting the gangrenous evolution of acute calculous cholecystitis. Methods: A retrospective study was conducted on 435 patients who underwent cholecystectomy between 2016 and 2024 at a tertiary care center. Patients were divided into gangrenous (n = 145) and chronic (n = 290) cholecystitis groups. Preoperative hematological parameters were used to calculate AISI, SII, and SIRI. After histopathological confirmation, patients with GC (gangrenous calculous cholecystitis) were identified, and for each case, two age- and sex-matched controls with chronic CC (calculous cholecystitis) were selected, maintaining a GC:CC ratio of 1:2. Preoperative hematological parameters were used to calculate AISI, SII, and SIRI. Results: All three indices were significantly higher in the gangrenous group (p < 0.001). Logistic regression identified SIRI as the strongest independent predictor of gangrenous cholecystitis (OR = 1.976, p < 0.001). ROC analysis demonstrated excellent discriminative capacity for all markers (AUC > 0.8), with SII achieving the highest diagnostic accuracy (AUC = 0.889, sensitivity 79.5%, specificity 86.3%). Conclusions: AISI, SII, and SIRI represent reliable, easily obtainable, and noninvasive biomarkers for assessing inflammatory severity and predicting gangrenous transformation in acute calculous cholecystitis. Their integration into preoperative evaluation could improve early risk stratification, surgical planning, and patient outcomes.